Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P755 | DOI: 10.1530/endoabs.35.P755

ECE2014 Poster Presentations Obesity (53 abstracts)

Anthropometric and metabolic parameters in 46 hypogonadal men with obesity grade III improve upon long-term treatment with testosterone undecanoate (TU) injections: Observational data from two registry studies

Farid Saad 1, , Ahmad Haider 3 , Aksam Yassin 4, , Gheorghe Doros 6 & Abdulmaged Traish 7


1Global Medical Affairs Men’s Healthcare, Bayer Pharma, Berlin, Germany; 2Gulf Medical University School of Medicine, Ajman, United Arab Emirates; 3Private Urology Practice, Bremerhaven, Germany; 4Institute of Urology and Andrology, Norderstedt, Germany; 5Dresden International University, Dresden, Germany; 6Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, Massachusetts, US; 7Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, Massachusetts, USA.


Introduction: Numerous studies have reported inverse associations between testosterone and obesity as well as other components of the metabolic syndrome.

Methods: From two registry studies of 561 hypogonadal mens, 46 mens with obesity grade III (BMI ≧40 kg/m2) were selected. All patients received TU injections for up to 6 years. 46 mens were followed for 2 years, 43 for 3 years, 37 for 4 years, 34 for 5 years, and 24 for 6 s. Declining numbers are result of the registry design.

Results: Weight (kg) decreased from 129.02±5.67 to 103.33±4.17, mean change from baseline −27.15±0.74 kg, percent change from baseline −20.99±3.16%. Waist circumference (cm) decreased from 118.41±5.69 to 106.48±4.91, mean change from baseline 12.44±0.36 cm. BMI (kg/m2) decreased from 41.93±1.5 to 33.62±1.58, mean change from baseline −8.79±0.23 kg/m2.

Mean fasting glucose (mg/dl) decreased from 115.48±23.85 to 96.54±2.9 (P<0.0001), mean change from baseline −18.48±2.96 mg/dl, HbA1c (%) from 7.57±1.38 to 6.08±0.5, mean change from baseline −1.61±0.13%.

Total cholesterol (TC; mg/dl) decreased from 306.76±43.03 to 192.23±9.17 (<0.0001), LDL (mg/dl) from 190.57±36.6 to 136.24±28.07 (P<0.0001), triglycerides (mg/dl) from 326.87±60.21 to 194.4±12.59 (P<0.0001). HDL (mg/dl) increased from 62.76±18.7 to 72.55±13.34 (P<0.0001). The TC:HDL ratio declined from 5.47±2.57 to 2.75±0.59 (P<0.0001). Systolic blood pressure (mmHg) decreased from 161.04±14.3 to 142.05±9.57, diastolic blood pressure from 97.07±10.91 to 80.89±6.76.

Liver enzymes AST and ALT (U/L) decreased from 42.39±17.84 to 20.33±1.9 and from 43.52±20.68 to 20.43±2.75 respectively (P<0.0001 for both), suggesting a reduction in liver fat content.

C-reactive protein (CRP, mg/l) declined from 3.96±4.31 to 0.57±0.59 (P<0.0001).

There were no drop-outs.

Conclusions: All changes were in a clinically meaningful magnitude and sustainable for the full observation period. TRT seems to be an effective approach to achieve sustained weight loss in excessively obese hypogonadal men.

Article tools

My recent searches

No recent searches.